Keyphrases
ST-elevation Myocardial Infarction (STEMI)
100%
Randomized Controlled Trial
42%
Percutaneous Coronary Intervention
41%
Primary Percutaneous Coronary Intervention
38%
Myocardial Infarction Patients
35%
Myocardial Salvage
34%
Symptom Duration
31%
Final Infarct Size
28%
Myocardial Salvage Index
28%
Symptom Onset
26%
Ischemic Heart Disease
25%
Prognostic Value
23%
Clinical Characteristics
23%
Patient-initiated
21%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
21%
Invasive Treatment
21%
Invasive Examination
21%
Primary PCI
21%
Troponin
21%
Exenatide
21%
Antibiotic Treatment
21%
Glucagon-like
21%
National Cohort Study
21%
Acute Coronary Syndrome
21%
Reperfusion
21%
Invasive Coronary Angiography
21%
Left-handed
21%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
21%
Patients Included
21%
Acute Treatment
21%
Copeptin
21%
Lactate Clearance
21%
Blood Glucose
21%
Lipid-lowering Treatment
21%
MR-proADM
21%
Endocarditis
21%
Stable Conditions
21%
Oral Antibiotics
21%
Glucose Clearance
21%
T-ratio
21%
Prognostic Marker
21%
Heart Rate
21%
Comatose Patients
21%
Out-of-hospital Cardiac Arrest
21%
Hazard Ratio
19%
All-cause Mortality
18%
Confidence Interval
17%
Heart Failure
17%
Trial Participants
16%
Early Invasive Strategy
16%
Medicine and Dentistry
ST Segment Elevation Myocardial Infarction
69%
Percutaneous Coronary Intervention
59%
Infarction
45%
Acute Coronary Syndrome
42%
Randomized Controlled Trial
42%
Primary Percutaneous Coronary Intervention
36%
Ischemic Heart Disease
25%
Revascularization
23%
Electrocardiogram
23%
Cohort Analysis
23%
Diagnosis
21%
Coronary Angiography
21%
Copeptin
21%
Troponin T
21%
ST Elevation
21%
Proprotein Convertase 9
21%
Cardiac Magnetic Resonance Imaging
16%
Pharmacology, Toxicology and Pharmaceutical Science
ST Segment Elevation Myocardial Infarction
73%
Acute Coronary Syndrome
42%
Infarction
42%
Randomized Controlled Trial
42%
Ischemic Heart Disease
25%
Cohort Study
23%
Congestive Heart Failure
21%
Proprotein Convertase 9
21%
Copeptin
21%
Endocarditis
21%
Troponin T
21%
Major Adverse Cardiac Event
21%
Proadrenomedullin
21%
Out of Hospital Cardiac Arrest
21%
Lactic Acid
21%
Exendin 4
21%
Glucagon-Like Peptide-1
21%
Heart Infarction
19%